PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-32.96%
Both companies show declining cash positions (-32.96% vs AGEN's -15.02%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-32.96%
Cash + STI yoy ≥ 1.5x AGEN's -21.85%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.20%
≥ 1.5x AGEN's -19.76%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-7.82%
Below half AGEN's 0.45%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
305.95%
≥ 1.5x AGEN's 0.74%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-28.88%
≥ 1.5x AGEN's -13.17%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-28.35%
Above 1.5x AGEN's -5.10%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-25.97%
1.1-1.25x AGEN's -20.92%. Bill Ackman wonders if the firm is incurring more one-time charges than competitor.
-23.54%
Above 1.5x AGEN's -9.47%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-23.54%
Above 1.5x AGEN's -0.20%. Michael Burry sees a potential leverage warning sign.
2.39%
Above 1.5x AGEN's 0.91%. Michael Burry suspects heavy new equity expansion or dilution.
-4.88%
1.25-1.5x AGEN's -3.35%. Bruce Berkowitz notes stronger reinvestment strategy.
-7.49%
Less than half of AGEN's -37.83%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-31.10%
Below half AGEN's -296.31%. Michael Burry sees potential underperformance in building shareholder capital.
-28.88%
≥ 1.5x AGEN's -13.17%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
32.96%
Less than half of AGEN's 105.05%. David Dodd sees better deleveraging or stronger cash buildup than competitor.